WO2016110226A1 - A novel anti-egfr monoclonal antibody, method of making, and use thereof - Google Patents
A novel anti-egfr monoclonal antibody, method of making, and use thereof Download PDFInfo
- Publication number
- WO2016110226A1 WO2016110226A1 PCT/CN2016/070024 CN2016070024W WO2016110226A1 WO 2016110226 A1 WO2016110226 A1 WO 2016110226A1 CN 2016070024 W CN2016070024 W CN 2016070024W WO 2016110226 A1 WO2016110226 A1 WO 2016110226A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- egfr
- seq
- gal
- amino acid
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract description 3
- 238000000034 method Methods 0.000 claims abstract description 61
- 230000005847 immunogenicity Effects 0.000 claims abstract description 21
- 241000699802 Cricetulus griseus Species 0.000 claims abstract description 13
- 108020004705 Codon Proteins 0.000 claims abstract description 7
- 238000012258 culturing Methods 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 50
- 102000001301 EGF receptor Human genes 0.000 claims description 27
- 206010028980 Neoplasm Diseases 0.000 claims description 27
- 108060006698 EGF receptor Proteins 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 24
- 206010009944 Colon cancer Diseases 0.000 claims description 23
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 23
- 150000004676 glycans Chemical class 0.000 claims description 22
- FDJKUWYYUZCUJX-KVNVFURPSA-N N-glycolylneuraminic acid Chemical compound OC[C@H](O)[C@H](O)[C@@H]1O[C@](O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO FDJKUWYYUZCUJX-KVNVFURPSA-N 0.000 claims description 20
- 229960004768 irinotecan Drugs 0.000 claims description 20
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 20
- SUHQNCLNRUAGOO-UHFFFAOYSA-N N-glycoloyl-neuraminic acid Natural products OCC(O)C(O)C(O)C(NC(=O)CO)C(O)CC(=O)C(O)=O SUHQNCLNRUAGOO-UHFFFAOYSA-N 0.000 claims description 19
- FDJKUWYYUZCUJX-UHFFFAOYSA-N N-glycolyl-beta-neuraminic acid Natural products OCC(O)C(O)C1OC(O)(C(O)=O)CC(O)C1NC(=O)CO FDJKUWYYUZCUJX-UHFFFAOYSA-N 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 19
- 201000011510 cancer Diseases 0.000 claims description 18
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 16
- 238000004458 analytical method Methods 0.000 claims description 15
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 14
- 238000004113 cell culture Methods 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 12
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 11
- 238000012216 screening Methods 0.000 claims description 11
- 238000002560 therapeutic procedure Methods 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 238000002296 dynamic light scattering Methods 0.000 claims description 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 8
- -1 Gal-α (1, 3) -Gal glycan Chemical class 0.000 claims description 7
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 239000001963 growth medium Substances 0.000 claims description 7
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 210000001672 ovary Anatomy 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 238000001959 radiotherapy Methods 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 4
- 206010063569 Metastatic squamous cell carcinoma Diseases 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 238000002512 chemotherapy Methods 0.000 claims description 4
- 229960002949 fluorouracil Drugs 0.000 claims description 4
- 229910052697 platinum Inorganic materials 0.000 claims description 4
- 230000000306 recurrent effect Effects 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000001802 infusion Methods 0.000 claims description 3
- 230000003204 osmotic effect Effects 0.000 claims description 3
- 229960001756 oxaliplatin Drugs 0.000 claims description 3
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 3
- 230000003442 weekly effect Effects 0.000 claims description 3
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 claims description 2
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims description 2
- CZMRCDWAGMRECN-FBXJDJJESA-N D-sucrose Chemical compound O[C@@H]1[C@@H](O)[C@H](CO)O[C@]1(CO)O[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](CO)O1 CZMRCDWAGMRECN-FBXJDJJESA-N 0.000 claims description 2
- 101710113436 GTPase KRas Proteins 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- KDQPSPMLNJTZAL-UHFFFAOYSA-L disodium hydrogenphosphate dihydrate Chemical compound O.O.[Na+].[Na+].OP([O-])([O-])=O KDQPSPMLNJTZAL-UHFFFAOYSA-L 0.000 claims description 2
- JYEFSHLLTQIXIO-SMNQTINBSA-N folfiri regimen Chemical compound FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 JYEFSHLLTQIXIO-SMNQTINBSA-N 0.000 claims description 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims description 2
- 235000008191 folinic acid Nutrition 0.000 claims description 2
- 239000011672 folinic acid Substances 0.000 claims description 2
- 238000011221 initial treatment Methods 0.000 claims description 2
- 229960001691 leucovorin Drugs 0.000 claims description 2
- 150000007523 nucleic acids Chemical group 0.000 claims description 2
- 239000013612 plasmid Substances 0.000 claims description 2
- 229950008882 polysorbate Drugs 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 238000007796 conventional method Methods 0.000 claims 1
- 238000005516 engineering process Methods 0.000 abstract description 4
- 230000002194 synthesizing effect Effects 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 description 22
- 229960005395 cetuximab Drugs 0.000 description 22
- 206010020751 Hypersensitivity Diseases 0.000 description 20
- 230000014509 gene expression Effects 0.000 description 20
- 238000011282 treatment Methods 0.000 description 17
- 208000026935 allergic disease Diseases 0.000 description 15
- 230000013595 glycosylation Effects 0.000 description 15
- 238000006206 glycosylation reaction Methods 0.000 description 15
- 230000009610 hypersensitivity Effects 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 14
- 229940082789 erbitux Drugs 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 10
- 206010061818 Disease progression Diseases 0.000 description 9
- 230000005750 disease progression Effects 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- 101000718529 Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) Alpha-galactosidase Proteins 0.000 description 8
- NNISLDGFPWIBDF-MPRBLYSKSA-N alpha-D-Gal-(1->3)-beta-D-Gal-(1->4)-D-GlcNAc Chemical compound O[C@@H]1[C@@H](NC(=O)C)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@@H](CO)O1 NNISLDGFPWIBDF-MPRBLYSKSA-N 0.000 description 8
- 229920001542 oligosaccharide Polymers 0.000 description 8
- 150000002482 oligosaccharides Chemical class 0.000 description 8
- 102000005348 Neuraminidase Human genes 0.000 description 7
- 108010006232 Neuraminidase Proteins 0.000 description 7
- 230000001988 toxicity Effects 0.000 description 7
- 231100000419 toxicity Toxicity 0.000 description 7
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 6
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 5
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000004481 post-translational protein modification Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- 102000009465 Growth Factor Receptors Human genes 0.000 description 4
- 108010009202 Growth Factor Receptors Proteins 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 238000001215 fluorescent labelling Methods 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 125000005629 sialic acid group Chemical group 0.000 description 4
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000007640 basal medium Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 229960000074 biopharmaceutical Drugs 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000004885 tandem mass spectrometry Methods 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- ODDPRQJTYDIWJU-UHFFFAOYSA-N 3'-beta-D-galactopyranosyl-lactose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(OC2C(OC(O)C(O)C2O)CO)OC(CO)C1O ODDPRQJTYDIWJU-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 108060002716 Exonuclease Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 2
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 2
- 108091008606 PDGF receptors Proteins 0.000 description 2
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 108091006629 SLC13A2 Proteins 0.000 description 2
- 108090000992 Transferases Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000011374 additional therapy Methods 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 125000003169 alpha-Gal epitope group Chemical group [C@H]1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)O[C@@H]1[C@H]([C@@H](O[C@@H]([C@@H]1O)CO)O[C@H]1[C@@H]([C@H](C(O[C@@H]1CO)*)NC(C)=O)O)O 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000001851 biosynthetic effect Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229940121647 egfr inhibitor Drugs 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 102000013165 exonuclease Human genes 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000004017 serum-free culture medium Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229940126622 therapeutic monoclonal antibody Drugs 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- WAVYAFBQOXCGSZ-UHFFFAOYSA-N 2-fluoropyrimidine Chemical compound FC1=NC=CC=N1 WAVYAFBQOXCGSZ-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 description 1
- 102000000796 CD79 Antigens Human genes 0.000 description 1
- 108010001445 CD79 Antigens Proteins 0.000 description 1
- 101150052200 CS gene Proteins 0.000 description 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 101150074155 DHFR gene Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 108091006020 Fc-tagged proteins Proteins 0.000 description 1
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 102000051366 Glycosyltransferases Human genes 0.000 description 1
- 108700023372 Glycosyltransferases Proteins 0.000 description 1
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 description 1
- 102000004584 Somatomedin Receptors Human genes 0.000 description 1
- 108010017622 Somatomedin Receptors Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- HSCJRCZFDFQWRP-ABVWGUQPSA-N UDP-alpha-D-galactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-ABVWGUQPSA-N 0.000 description 1
- HSCJRCZFDFQWRP-UHFFFAOYSA-N Uridindiphosphoglukose Natural products OC1C(O)C(O)C(CO)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-UHFFFAOYSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- QIGJYVCQYDKYDW-SDOYDPJRSA-N alpha-D-galactosyl-(1->3)-D-galactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@@H](O)[C@@H](CO)OC(O)[C@@H]1O QIGJYVCQYDKYDW-SDOYDPJRSA-N 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000013377 clone selection method Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 238000002013 hydrophilic interaction chromatography Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 150000005054 naphthyridines Chemical class 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 150000005255 pyrrolopyridines Chemical class 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Definitions
- the present invention relates to biotechnology, particularly the producing method and applications of a novel anti-EGFR monoclonal antibody.
- Tumor particularly malignant tumor
- Tumor is a disease which cause serious harm to human health in today’s world, and is the 2 nd deadly among all diseases. But in recent years, the incidence rate was significantly increased.
- the malignant cancer has poor treatment, accompanied with high metastasis rate at late stage and poor prognosis.
- Proliferation of normal cells is strictly controlled by respective ligands activating their growth factor receptors, such as growth factor receptor tyrosine kinases. Cancer cell proliferation is also through its factor receptor activation, but it loses the strict control of normal proliferation. This loss of control may be caused by many reasons, such as growth factor over-expression, overexpression of growth factor receptors, or spontaneous activation of biochemical pathways regulated by growth factors.
- Oncogenic receptors include epidermal growth factor receptor (EGFR) , platelet derived growth factor receptor (PDGFR) , insulin-like growth factor receptor ( (IGFR) , nerve growth factor receptor (NGFR) , and fibroblast growth factor receptor ( (FGF) etc.
- Epidermal growth factor receptor is also known as c-erbB1/HER1, whose family members are growth factor receptor tyrosine kinases, their cell surface with specific growth factors or natural ligand interactions, such as with EGF or TGF ci interactions, thereby activating the receptor tyrosine kinases.
- the first member of the family has been found to be a glycoprotein with apparent molecular weight of 165KD.
- EGFR plays an important role in the regulation of tumor cell growth, repair and survival, angiogenesis, invasion and metastasis, and is expressed in a considerable number of human tumors. In many malignant tumors, the expression of EGFR is often associated with a poor prognosis and a low survival rate. Based on this, if there is a drug which can block EGFR activity, it will inhibit the phosphorylation and signal transduction, thus play an anti-tumor functions in multiple aspects, and increase the anti-tumor chemotherapy and radiotherapy treatment. In some studies, EGFR inhibitors show addictive and synergistic effects when used in combined treatment with various chemotherapy drugs and radiation therapy drugs for certain cancers.
- EGFR inhibitors include monoclonal antibodies, tyrosine kinase inhibitors, quinazoline pyrrolo-/pyrrolo-/pyridopyridines, ligand-toxin and immunotoxin complexes, as well as antisense oligonucleotides and EGFR/ligand mediated vaccines.
- the anti-EGFR antibody can successfully inhibit the growth of EGFR-expressing tumor cell lines.
- the results from some anti-EGFR monoclonal antibodies alone or their combination with traditional treatment methods are encouraging.
- Glycosylation is a protein important post-translational modifications. Protein molecular surface sugar chains can have a profound impact on the structure and function of the protein molecules, glycosylation as an important post-translation process, has a great impact on proper proteins folding, localization, immunogenicity and biological activity.
- the glycosylation and glycan structure of mAb antibody have strong correlation with its function, by affecting the binding of IgG molecules to FcRs, Clq and FeRn to regulate the antibody-dependent cellular cytotoxicity (ADCC) , complement-dependent cytotoxicity (CDC) and half-life of IgG molecules. Glycosylation also affects the safety features of mAb, particularly non-human glycans, and has potential immunogenicity.
- the glycans located in Fab functional region can affect both the safety and efficacy features of these drugs.
- Glycosylation is highly dependent on cell expression system and subclone selection, and many factors during cell culture, for example medium components, culture conditions will affect glycosylation, thereby affecting the biological activity, efficacy, immunogenicity and pharmacokinetics of therapeutic proteins.
- exogenous gene in mammalian cells includes gene transcription, mRNA translation and post-translational modifications etc. Post-translational modifications include glycosylation, phosphorylation, oligomerization, as well as the formation of intra-or intermolecular disulfide bonds between protein molecules.
- Post-translational modification is crucial to the function of the protein, so it may be necessary to express certain proteins with biological functions in mammalian cells, such as membrane proteins, antibodies and enzymes having specific catalytic function.
- CHO cells and mouse myeloma cells (NS0, SP2/0) expression system has currently become the golden standard as cell engineering system for therapeutic antibody and Fc-fusion proteins. According to statistics, 48% of currently approved therapeutic monoclonal antibodies are expressed in CHO cells, while 45% are expressed in murine cells (21% NS0 cells, 14%SP2/0 cells, 10%hybridoma cells) . Although the integrity of polypeptide chains in different expression systems and culture conditions seems unchanged, the changes of glycosylation types cannot be ignored.
- Cetuximab ( C225 mab) is a recombinant chimeric monoclonal antibody specifically targeting epidermal growth factor receptor (EGFR) , and was approved in many countries for the treatment of metastatic colorectal cancer and head and neck squamous cell carcinoma.
- EGFR epidermal growth factor receptor
- a number of studies have reported that the drug hypersensitivity reactions occur at very high incidence in clinical applications.
- Drug specific IgE antibodies were found in the serum of most patients with hypersensitivity reactions, and it specifically reacts against ⁇ -Gal.
- ⁇ -Gal is a harmful non-human disaccharide, found in certain glycans on mAb, especially mAb expressed in the murine cell lines. High levels of anti- ⁇ -Gal IgE antibodies were found in some patients.
- NGNA N-hydroxyethyl neuraminidase
- NANA N-acetyl phenol neuraminidase
- the present inventors use CHO cells as host cells, culture cells in serum-free condition, successfully produce genetically engineered anti-EGFR antibody (CMAB009 mAb) with different glycan structures. Because this antibody does not contain the ⁇ -Gal glycan structure, it would not cause drug-specific IgE antibody-mediated hypersensitivity; there are no endogenous retrovirus particles in the engineered cells, there is no contamination in the antibody obtained from the cell culture of the engineered cells.
- the anti-EGFR monoclonal antibody prepared by this method has better clinical safety than mAb.
- a novel method of producing an anti-EGFR monoclonal antibody comprising:
- a novel anti-EGFR monoclonal antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO: 2 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 4;
- the coding sequences for the light chain and heavy chain of the novel anti-EGFR monoclonal antibody are designed and synthesized according to the codons mostly preferred by Chinese hamster.
- the host cell is Eukaryotic mammalian CHO cell.
- the cell culture temperature is 33°C ⁇ 36°C, preferably 34°C.
- the pH of the cell culture growth media is 6.5 ⁇ 6.9, preferably pH6.6.
- the osmotic pressure of the cell culture growth media is 290 mOsm/kg ⁇ 350mOsm/kg, preferably 340mOsm/kg.
- the culture media is serum-free culture media, and the host cell is cultured in serum-free condition.
- a composition comprising the antibody of CMAB009, and a pharmaceutically acceptable carrier.
- a method of producing drug comprising the novel anti-EGFR monoclonal antibody of CMAB009 to treat tumors expressing epidermal growth factor receptor (EGFR) .
- EGFR epidermal growth factor receptor
- a method of treating tumors expressing epidermal growth factor receptor (EGFR) with drug comprising the composition of CMAB009 and a pharmaceutically acceptable carrier.
- a methodof further comprising administering in combination with other drugs treating tumors expressing epidermal growth factor receptor (EGFR) .
- EGFR epidermal growth factor receptor
- a liquid pharmaceutical composition comprising water and an anti-EGFR antibody
- the anti-EGFR antibody comprises a light chain comprising the amino acid sequence set forth in SEQ ID NO: 2 and a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 4, wherein the antibody has a z-average (z-avg) of about 10-25 nm as determined by dynamic light scattering (DLS) analysis, and wherein the anti-EGFR antibody does not comprise an N-glycolylneuraminic acid (NGNA) , does not comprise a Gal- ⁇ (1, 3) -Gal glycan, and/or does comprise a Gal- ⁇ (2, 3/6) -Gal glycan.
- NGNA N-glycolylneuraminic acid
- composition comprising water and an anti-EGFR antibody, wherein the z-avg of the antibody is 15-20 nm.
- a method of treating a human subject having cancer comprising administering the composition to the subject, such the cancer is treated.
- a method of inhibiting progression of cancer in a human subject comprising administering the composition to the subject, such progression is inhibited.
- the cancer is squamous cell carcinoma of the head and neck (SCCHN) or colorectal cancer.
- the colorectal cancer is K-Ras Wild-type, EGFR-expressing colorectal cancer.
- the antibody is administered in combination with FOLFIRI (irinotecan, 5-fluorouracil, leucovorin) .
- FOLFIRI irinotecan, 5-fluorouracil, leucovorin
- the antibody is administered in combination with irinotecan.
- the subject has recurrent or metastatic squamous cell carcinoma of the head and neck and has failed prior platinum-based therapy.
- the subject has locally or regionally advanced squamous cell carcinoma of the head and neck.
- the antibody is administered in combination with radiation therapy for the initial treatment of the cancer.
- the subject has recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck.
- the antibody is administered in combination with platinum-based therapy with 5-FU.
- the antibody is administered in combination with an additional therapeutic agent.
- the additional therapeutic agent is a chemotherapeutic agent.
- the subject has failed oxaliplatin and fluoopyrimidine-based chemotherapy.
- a method of treating or inhibiting progression of colorectal cancer in a subject having colorectal cancer comprising administering an anti-EGFR antibody and irinotecan, such that colorectal cancer is treated, wherein the antibody comprises a light chain comprising the amino acid sequence set forth in SEQ ID NO: 2, comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 4, and contains a Gal- ⁇ (2, 3/6) -Gal glycan.
- a method of treating or inhibiting progression of colorectal cancer in a subject having colorectal cancer comprising administering an anti-EGFR antibody and irinotecan, such that colorectal cancer is treated, wherein the antibody comprises a light chain comprising the amino acid sequence set forth in SEQ ID NO: 2, comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 4, and does not contain either an N-glycolylneuraminic acid (NGNA) glycan or a Gal- ⁇ (1, 3) -Gal glycan.
- NGNA N-glycolylneuraminic acid
- the colorectal cancer is advanced colorectal cancer.
- the antibody is administered via infusion to the subject at an initial dose of 400 mg/m 2 followed by a weekly dose of 250 mg/m 2 .
- the antibody is produced in a Chinese Hamster Ovary (CHO) cell.
- a liquid pharmaceutical composition comprising water and an anti-EGFR antibody
- the anti-EGFR antibody comprises a light chain comprising the amino acid sequence set forth in SEQ ID NO: 2 and a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 4, wherein the anti-EGFR antibody is produced in a Chinese Hamster Ovary (CHO) cell, and wherein the composition does not comprise a polysorbate and/or a saccharobiose.
- a liquid pharmaceutical composition consisting essentially of water, an anti-EGFR antibody, sodium chloride, sodium dihydrogen phosphate dihydrate, and disodium phosphate dihydrate, wherein the anti-EGFR antibody comprises a light chain comprising the amino acid sequence set forth in SEQ ID NO: 2 and a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 4, and wherein the anti-EGFR antibody does not comprise an N-glycolylneuraminic acid (NGNA) glycan, does not comprise a Gal- ⁇ (1, 3) -Gal glycan, and/or does comprise a Gal- ⁇ (2, 3/6) -Gal glycan.
- NGNA N-glycolylneuraminic acid
- FIG. 5 graphically depicts the progression free survival (PFS) in the CMAB009 study described in Example 9.
- PFS is defined as the time from randomization until objective tumor growth progression or death.
- FIG. 6 graphically depicts overall survival (OS) of patients in the CMAB009 study described in Example 9.
- Figure 7 graphically depicts characterization of CMAB009 versus Erbitux using DLS methods to determine size distribution.
- CMAB009 is an anti-EGFR antibody that is produced in CHO cells and has the amino acid sequences of cetuximab.
- administration of CMAB009 to patients having cancer showed reduced immunogenicity reactions and improved efficacy, including an increase in the time in which the disease progressed.
- cetuximab refers to an anti-EGFR antibody having a light chain comprising the amino acid sequence set forth in SEQ ID NO: 2, and a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 4.
- the sequences of the cetuximab light and heavy chains are described below:
- variable region of light chain the CDRs were marked yellow
- variable region of light chain the CDRs were marked yellow
- the term “CMAB009” refers to a cetuximab antibody which is produced in a CHO cell.
- the CMAB009 antibody comprises a light chain comprising the amino acid sequence set forth in SEQ ID NO: 1 and a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 3.
- the CMAB009 antibody does not contain either an N-glycolylneuraminic acid (NGNA) glycan or a Gal- ⁇ (1,3)-Gal glycan.
- NGNA N-glycolylneuraminic acid
- the CMAB009 antibody does contain glycans associated with CHO cell expression, including, for example, a Gal- ⁇ (2, 3/6)-Gal glycan.
- the term “in combination” when used in reference to administration of therapie refers to the use of two or more therapeutic agents, e.g., CMAB009 and irinotecan, to treat a disorder, e.g., metastatic colorectal cancer.
- CMAB009 and irinotecan e.g
- a first therapy can be administered before (e.g., 1 minute, 45 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks) , concurrently, or after (e.g., 1 minute, 45 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks) the administration of a second therapy to a subject who has had or has cancer.
- Any additional therapy can be administered in any order with the other additional therapies.
- the invention is based on the use of CHO cells to produce an improved anti-EGFR antibody that is more effective and safer than anti-EGFR antibodies produced in, for example, myeloma cells.
- the glycosylation mechanism in CHO cells is very similar to the IgG glycosylation mechanism in human, earlier studies suggest that the CHO cells lack biosynthetic mechanism of ⁇ -Gal epitope-containing glycoprotein, recent studies have reported the presence of ⁇ 1, 3 half galactosidase transferase gene in CHO cells, but it is at no or low expression state during the clone selection process, and it is unclear how this glycoside is ⁇ 1, 3-galactosidase transferase gene is activated in CHO cell line, presumably it associated with the transfection process, similar to other glycoside transferases.
- CMAB009 mAb genetically engineered anti-EGFR antibody
- Erbitux glycan contains a lot of ⁇ -Gal, and mostly NGNA as the terminal sialic acid, which has very high immunogenicity.
- CMAB009 mAb glycan does not contain ⁇ -Gal, and terminal sialic acid is mainly in the form of NANA.
- Subsequent clinical studies have confirmed that the antibody has a good tolerance, with no drug-related hypersensitivity observed, no IgE specific ADA detected.
- CMAB009 monoclonal antibody in vivo clearance is in line with the in vivo metabolic of chimeric antibodies, and the pharmacokinetic parameters are consistent with those of CMAB009 monoclonal antibody has initially achieved significant clinical efficacy, and is expected to bring the greatest benefits to potential patients of with hypersensitivity.
- CMABOO9 monoclonal antibody Compared with monoclonal antibody, CMABOO9 monoclonal antibody has the same amino acid primary structure, while does not contain ⁇ -Gal, and the terminal sialic acid is mainly the common human sialic acid form of N-acetylneuraminic acid (NANA) . This is consistent with the better tolerance we observed in clinical studies, while no drug-related hypersensitivity observed.
- NANA N-acetylneuraminic acid
- Preferred codons of Chinese hamster were chosen for making most efficient eukaryotic expression vector, so as to obtain more efficient expression in Chinese hamster ovary expression system.
- Hamsters preferred codons are shown in Table 1.
- Signal peptide is selected from Chinese hamster B cell antigen receptor complex associated protein ⁇ chain.
- the CMAB009 light chain comprises the nucleotide sequence of SEQ ID NO: 1 and the amino acid sequences of SEQ ID NO: 2
- the CMAB009 heavy chain comprises the nucleotide sequence SEQ ID NO: 3 and the amino acid sequence SEQ ID NO 4.
- host cells In the biopharmaceutical field selection of host cells needs to focus on several important aspects: glycosylation and other post-translational modifications types to avoid causing immunogenicity; host cells suitable for large-scale cultivation in bioreactors, and can grow to high density in chemically defined and animal component free (ACDF) medium; virus safety; suitable for cloning and pressure screening in the ACDF.
- ACDF chemically defined and animal component free
- CHO cell can grow at high density in bioreactors, is easy for genetic manipulation, has N-glycosylation similar to humans, lower the risk of virus transmission, and is widely used in the biopharmaceutical field.
- the most commonly used clone for industrial production is the CHO-K1, CHO-DXB11 and CHO-DG44.
- CHO-K1 is similar to the primary CHO cell, while DG44 and DXB11 were manipulated through random mutagenesis to remove DHFR gene, so they can be used for gene amplification via metabolic defects.
- CHO-K1 uses CS selection system, but has a lower screening efficiency because of the endogenous CS expression in CHO-K1.
- the present invention chose the more widely used CHO cells as host cells which are more suitable for industrial production of therapeutic antibodies, and performed proper engineering of CHO-K1.
- Example 3 Transfecting host cells and screening high expression clones
- Liposome based cotransfection of CHO-CR-GS -/- screening under the pressure of CS selection system were performed to obtain stable cell clones with highly efficient expression of anti-EGFR monoclonal antibody. After several rounds of transfection and screening, cell clones were obtained with expressing amount greater than 20pg/cell. day.
- basal medium for CHO-CR-G5 -/- , which is chemically defined type of medium (Chemical Defined, CD) , i.e. the medium is made by combining amino acids, vitamins, inorganic salt, glucose and trace elements according to cell growth needs and certain percentages.
- CD chemical Defined
- This basal medium can meet the initial growth needs of the engineered cells obtained from screening.
- optimizations were performed for the basal medium, including adding hormones, genetically engineered recombinant growth factors, adjusting amino acids amounts.
- the culture PH is: 6.5 ⁇ 6.9, preferably pH6.6; culture temperature is: 33 °C ⁇ 36 °C, preferably 34 °C; osmolality is: 290mOsm/kg ⁇ 350 mOsm/kg, preferably 340 mOsm/kg.
- culture (CHOM-B09) and supplemented medium (CHOM-S09) were ultimately determined suitable for the large scale serum-free culture of the engineered cells expressing anti-EGFR monoclonal antibody, with culture conditions: pH6.6, temperature 34 °C, and osmotic pressure of 340 mOsm/kg.
- the expression yield of the engineered cells is greater than 30pg/cell. day in the optimized medium, using Fed-batch culture mode.
- the yield of the desired antibody may be greater than 3g/L in the culture supernatant harvested after 2 weeks of culture period.
- the high expression clone obtained from the screening was cultured in expanded scale with serum-free culture medium, supernatant was collected, centrifuged at 9000rpm *20min, 4 °C, pellet and the cell debris was discarded. concentrated by ultrafiltration using ultrafiltration packets of 50KB membrane from Millipore Corporation, then centrifuged at 9000rpm *30min, 4 °C to remove cell debris, filtered with 0.45um membrane, used rProtein A (recombinant protein a) by affinity chromatography to do preliminary purification, in-situ wash buffer is 6M GuCl, the binding buffer for the column is 20mM PB + 150mM NaC1 pH7.0, after balancing with three to five column volumes, using three to five column volumes of elution buffer 20mM Citric Acid (citrate buffer) pH3.0 to elute.
- in-situ wash buffer is 6M GuCl
- the binding buffer for the column is 20mM PB + 150mM NaC1 pH7.0
- CMAB009 was characterized according to standard dynamic light scattering (DLS) analysis. It was determined that CMAB009 has a more homogenous size distribution in comparison to Erbitux.
- the z-average (z-avg) for Erbitux was determined to be 31.56 nm, while the z-avg. for CMAB009 was 16.79 nm.
- the polydispersity index (PDI) of Erbitux was determined to be 0.313, versus 0.128 for CMAB009.
- PDI polydispersity index
- Fc fragment and oligosaccharide from Fab were prepared after glucosidase digestion; oligosaccharides exonuclease treatment of oligosaccharides on Fab; 2-AB fluorescence labeling of oligosaccharides; After HILIC solid phase extraction to remove excess 2-AB, oligosaccharides were obtained with fluorescence labeled sugar chains, then analyzed via LC/MS and MS/MS chromatography.
- CMAB009 antibody and the original antibody Cetuximab each have two glycosylation sites, with exactly the same glycan chain structure on their Fc segments, results in Figure 1.
- Fab segments have different glycan chain structures, with mostly the sialic acid NANA glycan chain structure on CMAB009 Fab fragment, and mostly the sialic acid NGNA glycan chain structure on original Cetuximab Fab fragment;
- the glycans of CMAB009 Fab do not contain ⁇ -galactose, while the glycans of original Cetuximab Fab contain a large amount of ⁇ -galactose.
- LC/MS analysis of the glycan structure of the heavy chain Fab fragment is shown in Figure 2.
- An initial study enrolled a total of 18 subjects, with 3, 6, 6 subjects each assigned to dose groups of 100 mg/m 2 dose, 250 mg/m 2 dose and 400 mg/m 2 dose, respectively, in the study of single intravenous administration.
- 3 subjects withdrew due to disease progression according to the study design the remaining 15 subjects multiple administration inclusion criteria were enrolled in the multiple dose group meeting, with 3 extra subjects were enrolled to multiple dose (Table 1)
- Subjects enrolled in this study were refractory to effective conventional treatment methods, experienced failure from conventional treatment or patients with relapse of advanced cancers, including 10 cases of colorectal cancer, 7 cases of lung cancer, 1 case of gastric cancer, the demographic statistical characteristics and prior treatment of the subjects are shown in Table 2.
- CMAB009 monoclonal antibody clinical safety most adverse events were drug-related rash, there were no clinically significant new toxicity observed, and there no was severe hypersensitivity observed among the 73 subjects.
- Immunogenicity is an important aspect in biopharmaceutical safety assessment.
- Traditional ELISA can be used for immunogenicity analysis, but the problem is, theoretically, the coated Fab segments for capturing antibody should be oriented to the optimal confirmation to facilitate the antigen-antibody interaction, the Fab fragments for capturing sometimes ae partially or entirely bound to microtiter plates, which results in the reduction of antibody capturing activity.
- biosensors made with biofilm interference technology and optical fibers were employed, in which the bottom was covered with SA ligands conjugated with biomolecule compatible layers.
- the biofilm thickness increases, reflected light interference spectral curve drift a measurable distance, thereby enabling real-time measurement of intermolecular interactions.
- This method is equivalent to the self-assembly process of the captured antibodies, which formed a range of optimal conformations at a certain density for capturing antibody on the surface of the biosensor, which not only improves the analytical sensitivity but also increases the linear range, which helps reduce the false-positive reactions from non-specific binding.
- Example 9 CMAB009 treatment results in improved efficacy for treating cancer and reduced immunogenicity
- CMAB009 was administered to patients having metastatic colorectal cancer in a Phase 2/3 study to determine the efficacy and immunogenicity of CMAB009. As described below, the results from the study were then compared to similar studies performed using (cetuximab) . Surprisingly, it was determined that CMAB009 has additional efficacy beyond that known for For example, CMAB009 was able to increase the overall survival and length of time to disease progression in patients. The below study is comparable to the (cetuximab) study described in Alberto F. Sobrero, et al. Clin Oncol, 2008, 26: 2311-2319.
- CMAB009 study was initiated by screening patients to identify those with 1) histological confirmed metastatic colorectal adenocarcinoma, 2) KRAS wild-type tumors, EGFR-expressing or EGFR-noexpressiong by immunohistochemistry, 3) has measurable lesion, at least 1cm in diametre by CT or MRI, at least 2cm diameter by physical examination or other iconography, 4) ECOG performance status 0 to 1, 5) failure (disease progression/discontinuation due to toxicity ) of fluoropyrimidine and oxaliplatin treatment, stop at least one month thereafter, . 501 patients were identified and randomized in a 2: 1 manner to group 1 or group 2.
- Group 1 included 337 patients who were administered a combination of CMAB009 and irinotecan. Specifically, the patients in group 1 were administered an initial dose of 400 mg/m 2 of CMAB009 followed by weekly infusions of 250 mg/m 2 thereafter. Irinotecan doses were maintained 180mg/m2 every 2 weeks. Group 2 included 164 patients who were administered irinotecan monotherapy at a dose consistent with the patient’s therapy prior to the study. Patients in both groups were treated until the disease progressed or the patient reached an unacceptable level of toxicity. Patient baseline characteristics are provided in Table 5.
- CMAB009 When compared to data reported for (cetuximab) from a similar study (see Alberto F. Sobrero, et al. Clin Oncol, 2008, 26: 2311-2319) , patients receiving CMAB009 showed better overall survival (10.7 months for patients receiving (cetuximab) + irinotecan vs. 17.6 months for patients receiving CMAB009 + irinotecan) and an incrased time to disease progression (4.0 months for patients receiving (cetuximab) + irinotecan vs, 5.6 months for patients receiving CMAB009 + irinotecan) .
- CMAB009 When compared to reported data for surprisingly the overall survival of the patients was greater in the patients receiving CMAB009, i.e., 10.7 months for Erbitux (cetuximab) + irinotecan vs. 17.5 months for CMAB009 + irinotecan.
- Figure 5 Data showing an increase in disease progression from this CMAB009 study is also provided in Figure 5 (compare to published Erbitux (cetuximab) data; see Figure 3 of Alberto F. Sobrero, et al. Clin Oncol, 2008, 26: 2311-2319.
- Figure 6 Data showing an increase in overall survival from this CMAB009 study is also provided in Figure 6 (compare to published Erbitux (cetuximab) data; see Figure 2 of Alberto F. Sobrero, et al. Clin Oncol, 2008, 26: 2311-2319) .
- CMAB009 surprisingly was not only more effective than Erbitux (cetuximab) , providing, for example, a longer time to disease progression, but had a reduced rate of adverse events associated with hypersensitivity reactions, e.g., acne-like rash or diarrhea.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention provides a method for producing an anti-EGFR monoclonal antibody and the applications thereof. The method comprises the steps of: designing and synthesizing the light chain and heavy chain according to the codons preferred by Chinese hamster, transfecting GS knockout host cells CHO-CR-GS-/-, culturing cells using serum-free technology, isolating and purifying the antibody, and obtaining the low immunogenicity CMAB009 antibody.
Description
RELATED APPLICATIONS
This application claims priority to Chinese Patent Application No. 2015100062337, filed on January 7,2015.
The present invention relates to biotechnology, particularly the producing method and applications of a novel anti-EGFR monoclonal antibody.
Tumor, particularly malignant tumor, is a disease which cause serious harm to human health in today’s world, and is the 2nd deadly among all diseases. But in recent years, the incidence rate was significantly increased. The malignant cancer has poor treatment, accompanied with high metastasis rate at late stage and poor prognosis. Current conventional clinical treatment methods including radiotherapy, chemotherapy and surgery, which although largely alleviate the pain and prolong the survival time, have significant limitations, and are difficult to improve their efficacy further.
Proliferation of normal cells is strictly controlled by respective ligands activating their growth factor receptors, such as growth factor receptor tyrosine kinases. Cancer cell proliferation is also through its factor receptor activation, but it loses the strict control of normal proliferation. This loss of control may be caused by many reasons, such as growth factor over-expression, overexpression of growth factor receptors, or spontaneous activation of biochemical pathways regulated by growth factors. Oncogenic receptors include epidermal growth factor receptor (EGFR) , platelet derived growth factor receptor (PDGFR) , insulin-like growth factor receptor ( (IGFR) , nerve growth factor receptor (NGFR) , and fibroblast growth factor receptor ( (FGF) etc.
Epidermal growth factor receptor (EGFR) is also known as c-erbB1/HER1, whose family members are growth factor receptor tyrosine kinases, their cell surface with specific growth factors or natural ligand interactions, such as with EGF or TGF ci interactions, thereby
activating the receptor tyrosine kinases. The first member of the family has been found to be a glycoprotein with apparent molecular weight of 165KD.
EGFR plays an important role in the regulation of tumor cell growth, repair and survival, angiogenesis, invasion and metastasis, and is expressed in a considerable number of human tumors. In many malignant tumors, the expression of EGFR is often associated with a poor prognosis and a low survival rate. Based on this, if there is a drug which can block EGFR activity, it will inhibit the phosphorylation and signal transduction, thus play an anti-tumor functions in multiple aspects, and increase the anti-tumor chemotherapy and radiotherapy treatment. In some studies, EGFR inhibitors show addictive and synergistic effects when used in combined treatment with various chemotherapy drugs and radiation therapy drugs for certain cancers.
EGFR inhibitors include monoclonal antibodies, tyrosine kinase inhibitors, quinazoline pyrrolo-/pyrrolo-/pyridopyridines, ligand-toxin and immunotoxin complexes, as well as antisense oligonucleotides and EGFR/ligand mediated vaccines.
It was demonstrated in some in vivo and in vitro experiments that the anti-EGFR antibody can successfully inhibit the growth of EGFR-expressing tumor cell lines. In treatment of solid tumors, the results from some anti-EGFR monoclonal antibodies alone or their combination with traditional treatment methods are encouraging.
Glycosylation is a protein important post-translational modifications. Protein molecular surface sugar chains can have a profound impact on the structure and function of the protein molecules, glycosylation as an important post-translation process, has a great impact on proper proteins folding, localization, immunogenicity and biological activity. The glycosylation and glycan structure of mAb antibody have strong correlation with its function, by affecting the binding of IgG molecules to FcRs, Clq and FeRn to regulate the antibody-dependent cellular cytotoxicity (ADCC) , complement-dependent cytotoxicity (CDC) and half-life of IgG molecules. Glycosylation also affects the safety features of mAb, particularly non-human glycans, and has potential immunogenicity. The glycans located in Fab functional region can affect both the safety and efficacy features of these drugs.
Glycosylation is highly dependent on cell expression system and subclone selection, and many factors during cell culture, for example medium components, culture conditions will affect glycosylation, thereby affecting the biological activity, efficacy, immunogenicity and pharmacokinetics of therapeutic proteins.
Among the therapeutic monoclonal antibodies currently marketed, the vast majority is produced by recombinant DNA technology, and the vast majority use in vitro cell culture technology. Because of the complexity of mammalian cell structure, function and gene expression regulation, there is a big difference between the expression of exogenous genes in mammalian cells and that in prokaryotes, consequently, the machinery for efficient expression of exogenous genes is also different from that for prokaryotes cells. Expression of exogenous gene in mammalian cells includes gene transcription, mRNA translation and post-translational modifications etc. Post-translational modifications include glycosylation, phosphorylation, oligomerization, as well as the formation of intra-or intermolecular disulfide bonds between protein molecules. Post-translational modification is crucial to the function of the protein, so it may be necessary to express certain proteins with biological functions in mammalian cells, such as membrane proteins, antibodies and enzymes having specific catalytic function. CHO cells and mouse myeloma cells (NS0, SP2/0) expression system has currently become the golden standard as cell engineering system for therapeutic antibody and Fc-fusion proteins. According to statistics, 48％ of currently approved therapeutic monoclonal antibodies are expressed in CHO cells, while 45％ are expressed in murine cells (21％ NS0 cells, 14％SP2/0 cells, 10％hybridoma cells) . Although the integrity of polypeptide chains in different expression systems and culture conditions seems unchanged, the changes of glycosylation types cannot be ignored.
Cetuximab (
C225 mab) , is a recombinant chimeric monoclonal antibody specifically targeting epidermal growth factor receptor (EGFR) , and was approved in many countries for the treatment of metastatic colorectal cancer and head and neck squamous cell carcinoma. However, a number of studies have reported that the drug hypersensitivity reactions occur at very high incidence in clinical applications. Drug specific IgE antibodies were found in the serum of most patients with hypersensitivity reactions, and it specifically reacts against α-Gal. Further research found that, 
is expressed and prepared in mammalian cells (mouse myeloma cells SP2/0) , and this murine cell line containing an additional α1, 3-galactosidase transferase, which primarily mediates the transfer of galactose
residue is from UDP-Gal of α conformation to the terminal galactose residues, thereby generating α-Gal. α-Gal is a harmful non-human disaccharide, found in certain glycans on mAb, especially mAb expressed in the murine cell lines. High levels of anti-α-Gal IgE antibodies were found in some patients. If using mAb with glycan containing α-Gal units for treatment, there will be serious hypersensitivity reactions. Further, the difference of murine cell IgG glycosylation from human is that, murine cells not only have the biosynthetic machinery to produce α-Gal epitope, but also produce N-hydroxyethyl neuraminidase (NGNA) , rather than N-acetyl phenol neuraminidase (NANA) . The distinction of NGNA and NANA is there is an additional oxygen atom in NGNA, and glycoproteins are considered to be closely associated with the immunogenicity in humans if they contain NGNA residues. Some marketed therapeutic glycoproteins have cause serious adverse reactions in the patients because they contains NGNA residues.
SUMMARY OF THE INVENTION
In order to overcome the disadvantage of using SP2/0 cells as the host cell to produce anti-EGFR monoclonal antibody, it’s necessary to use a suitable host cell and optimize the culture conditions to reduce the differences between proteins expressed in cell culture and natural human proteins, so as to improve the drug safety for human.
The present inventors use CHO cells as host cells, culture cells in serum-free condition, successfully produce genetically engineered anti-EGFR antibody (CMAB009 mAb) with different glycan structures. Because this antibody does not contain the α-Gal glycan structure, it would not cause drug-specific IgE antibody-mediated hypersensitivity； there are no endogenous retrovirus particles in the engineered cells, there is no contamination in the antibody obtained from the cell culture of the engineered cells. The anti-EGFR monoclonal antibody prepared by this method has better clinical safety than
mAb.
A novel method of producing an anti-EGFR monoclonal antibody, said method comprising:
a) a novel anti-EGFR monoclonal antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO: 2 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 4；
b) constructing recombinant plasmid using nucleic acid fragment of SEQ ID NO: 1 and SEQ ID NO : 3, transfecting host cell, screening high-expressing clone；
c) optimizing cell culture conditions, culturing in large scale to produce novel anti-EGFR monoclonal antibody, isolating and purifying.
The coding sequences for the light chain and heavy chain of the novel anti-EGFR monoclonal antibody are designed and synthesized according to the codons mostly preferred by Chinese hamster.
The host cell is Eukaryotic mammalian CHO cell.
The cell culture temperature is 33℃ ～ 36℃, preferably 34℃.
The pH of the cell culture growth media is 6.5～6.9, preferably pH6.6.
The osmotic pressure of the cell culture growth media is 290 mOsm/kg～350mOsm/kg, preferably 340mOsm/kg.
The culture media is serum-free culture media, and the host cell is cultured in serum-free condition.
A composition comprising the antibody of CMAB009, and a pharmaceutically acceptable carrier.
A method of producing drug comprising the novel anti-EGFR monoclonal antibody of CMAB009 to treat tumors expressing epidermal growth factor receptor (EGFR) .
A method of treating tumors expressing epidermal growth factor receptor (EGFR) with drug comprising the composition of CMAB009 and a pharmaceutically acceptable carrier..
A methodof further comprising administering in combination with other drugs treating tumors expressing epidermal growth factor receptor (EGFR) .
A liquid pharmaceutical composition comprising water and an anti-EGFR antibody,
wherein the anti-EGFR antibody comprises a light chain comprising the amino acid sequence set forth in SEQ ID NO: 2 and a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 4, wherein the antibody has a z-average (z-avg) of about 10-25 nm as determined by dynamic light scattering (DLS) analysis, and wherein the anti-EGFR antibody does not comprise an N-glycolylneuraminic acid (NGNA) , does not comprise a Gal-α(1, 3) -Gal glycan, and/or does comprise a Gal-α (2, 3/6) -Gal glycan.
The composition comprising water and an anti-EGFR antibody, wherein the z-avg of the antibody is 15-20 nm.
A method of treating a human subject having cancer, said method comprising administering the composition to the subject, such the cancer is treated.
A method of inhibiting progression of cancer in a human subject, said method comprising administering the composition to the subject, such progression is inhibited.
The cancer is squamous cell carcinoma of the head and neck (SCCHN) or colorectal cancer.
The colorectal cancer is K-Ras Wild-type, EGFR-expressing colorectal cancer.
The antibody is administered in combination with FOLFIRI (irinotecan, 5-fluorouracil, leucovorin) .
The antibody is administered in combination with irinotecan.
The subject has recurrent or metastatic squamous cell carcinoma of the head and neck and has failed prior platinum-based therapy.
The subject has locally or regionally advanced squamous cell carcinoma of the head and neck.
The antibody is administered in combination with radiation therapy for the initial treatment of the cancer.
The subject has recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck.
The antibody is administered in combination with platinum-based therapy with 5-FU.
The antibody is administered in combination with an additional therapeutic agent.
The additional therapeutic agent is a chemotherapeutic agent.
The subject has failed oxaliplatin and fluoopyrimidine-based chemotherapy.
A method of treating or inhibiting progression of colorectal cancer in a subject having colorectal cancer, said method comprising administering an anti-EGFR antibody and irinotecan, such that colorectal cancer is treated, wherein the antibody comprises a light chain comprising the amino acid sequence set forth in SEQ ID NO: 2, comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 4, and contains a Gal-α (2, 3/6) -Gal glycan.
A method of treating or inhibiting progression of colorectal cancer in a subject having colorectal cancer, said method comprising administering an anti-EGFR antibody and irinotecan, such that colorectal cancer is treated, wherein the antibody comprises a light chain comprising the amino acid sequence set forth in SEQ ID NO: 2, comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 4, and does not contain either an N-glycolylneuraminic acid (NGNA) glycan or a Gal-α (1, 3) -Gal glycan.
The colorectal cancer is advanced colorectal cancer.
The antibody is administered via infusion to the subject at an initial dose of 400 mg/m2 followed by a weekly dose of 250 mg/m2.
The antibody is produced in a Chinese Hamster Ovary (CHO) cell.
A liquid pharmaceutical composition comprising water and an anti-EGFR antibody,
wherein the anti-EGFR antibody comprises a light chain comprising the amino acid sequence set forth in SEQ ID NO: 2 and a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 4, wherein the anti-EGFR antibody is produced in a Chinese Hamster Ovary (CHO) cell, and wherein the composition does not comprise a polysorbate and/or a saccharobiose.
A liquid pharmaceutical composition consisting essentially of water, an anti-EGFR antibody, sodium chloride, sodium dihydrogen phosphate dihydrate, and disodium phosphate dihydrate, wherein the anti-EGFR antibody comprises a light chain comprising the amino acid sequence set forth in SEQ ID NO: 2 and a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 4, and wherein the anti-EGFR antibody does not comprise an N-glycolylneuraminic acid (NGNA) glycan, does not comprise a Gal-α (1, 3) -Gal glycan, and/or does comprise a Gal-α (2, 3/6) -Gal glycan.
DESCRIPTION OF THE DRAWINGS
Figure 1 LC/MS analysis of Cetuximab and CMAB00 9 heavy chain Fc segment oligosaccharides fluorescence labeling chromatogram
Figure 2 LC/MS analysis of Cetuximab and CMAB009 heavy chain Fab fragment oligosaccharides fluorescence labeling chromatogram
Figure 3 Fortebio Octet immunogenicity analysis (Octet QK System)
Figure 4 Fortebio Octet immunogenicity analysis (Octet RED System)
Figure 5 graphically depicts the progression free survival (PFS) in the CMAB009 study described in Example 9. PFS is defined as the time from randomization until objective tumor growth progression or death.
Figure 6 graphically depicts overall survival (OS) of patients in the CMAB009 study described in Example 9.
Figure 7 graphically depicts characterization of CMAB009 versus Erbitux using DLS methods to determine size distribution.
The invention is based, at least in part, on the therapeutic advantages of producing an anti-EGFR antibody in Chinese Hamster Ovary (CHO) cells. CMAB009 is an anti-EGFR antibody that is produced in CHO cells and has the amino acid sequences of cetuximab. In comparison to
(cetuximab) , administration of CMAB009 to patients having cancer showed reduced immunogenicity reactions and improved efficacy, including an increase in the time in which the disease progressed.
As used herein, the term “cetuximab” refers to an anti-EGFR antibody having a light chain comprising the amino acid sequence set forth in SEQ ID NO: 2, and a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 4. The sequences of the cetuximab light and heavy chains are described below:
CDR1
CDR2
CDR3
CDR1
CDR2
CDR3
As used herein, the term “CMAB009” refers to a cetuximab antibody which is produced in a CHO cell. Thus, the CMAB009 antibody comprises a light chain comprising the amino acid sequence set forth in SEQ ID NO: 1 and a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 3. Further, the CMAB009 antibody does not contain either an N-glycolylneuraminic acid (NGNA) glycan or a Gal-α(1,3)-Gal glycan. The CMAB009 antibody does contain glycans associated with CHO cell expression, including, for example, a Gal-α(2, 3/6)-Gal glycan.
As used herein, the term “in combination” when used in reference to administration of therapie, srefers to the use of two or more therapeutic agents, e.g., CMAB009 and irinotecan, to treat a disorder, e.g., metastatic colorectal cancer. The use of the term “in combination” does not restrict the order in which therapies are administered to a subject with cancer. For example, a first therapy can be administered before (e.g., 1 minute, 45 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks) , concurrently, or after (e.g., 1 minute, 45 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks) the administration of a second therapy to a subject who has had or has cancer. Any additional therapy can be administered in any order with the other additional therapies.
The invention is based on the use of CHO cells to produce an improved anti-EGFR antibody that is more effective and safer than anti-EGFR antibodies produced in, for example, myeloma cells. The glycosylation mechanism in CHO cells is very similar to the IgG glycosylation mechanism in human, earlier studies suggest that the CHO cells lack biosynthetic mechanism of α-Gal epitope-containing glycoprotein, recent studies have reported the presence of α1, 3 half galactosidase transferase gene in CHO cells, but it is at no or low expression state during the clone selection process, and it is unclear how this glycoside is α1, 3-galactosidase transferase gene is activated in CHO cell line, presumably it associated with the transfection process, similar to other glycoside transferases. Based on this, we designed and selected CHO expression system and successfully prepared genetically engineered anti-EGFR antibody (CMAB009 mAb) with different glycan structures. By structure analysis, it was confirmed the Erbitux glycan contains a lot of α-Gal, and mostly NGNA as the terminal sialic acid, which has very high immunogenicity. CMAB009 mAb glycan does not contain α-Gal, and terminal sialic acid is mainly in the form of NANA. Subsequent clinical studies have confirmed that the antibody has a good tolerance, with no drug-related hypersensitivity observed, no IgE specific ADA detected. At the same time of greatly reduced immunogenicity, the characteristics of CMAB009 monoclonal antibody in vivo clearance is in line with the in vivo metabolic of chimeric antibodies, and the pharmacokinetic parameters are consistent with those of
CMAB009 monoclonal antibody has initially achieved significant clinical efficacy, and is expected to bring the greatest benefits to potential patients of with hypersensitivity.
Compared with
monoclonal antibody, CMABOO9 monoclonal antibody has the same amino acid primary structure, while does not contain α-Gal, and the terminal sialic acid is mainly the common human sialic acid form of N-acetylneuraminic acid (NANA) . This is consistent with the better tolerance we observed in clinical studies, while no drug-related hypersensitivity observed. At the same time of greatly reduced immunogenicity, the characteristics of CMAB009 monoclonal antibody in vivo clearance is in line with the in vivo metabolic of chimeric antibodies, and the pharmacokinetic parameters are consistent with those of
This study demonstrates that, it is effective to reducing the immunogenicity of monoclonal antibodies to prevent the occurrence of hypersensitivity, by modifying mAb glycosylation structure, while not affecting the biological activity and clearance characteristics of monoclonal antibody. This can reduce the incidence of clinical adverse reactions, and is expected to bring the greatest benefits to potential patients of hypersensitivity, and provide potential safe, tolerable and effectively targeting drugs.
EXAMPLES
The following embodiments, examples of the present invention are described in further details. However, it should be understood that these embodiments, examples are for illustration purposes only, but not intended to limit the invention.
Example 1: Construction of Eukaryotic expression vector
Preferred codons of Chinese hamster were chosen for making most efficient eukaryotic expression vector, so as to obtain more efficient expression in Chinese hamster ovary expression system. Hamsters preferred codons are shown in Table 1.
Table 1, Chinese hamster preferred codons
Signal peptide is selected from Chinese hamster B cell antigen receptor complex associated protein β chain. 
Designed and synthesized according to the most preferred codons of Chinese hamster, the CMAB009 light chain comprises the nucleotide sequence of SEQ ID NO: 1 and the amino acid sequences of SEQ ID NO: 2, the CMAB009 heavy chain comprises the nucleotide sequence SEQ ID NO: 3 and the amino acid sequence SEQ ID NO 4. The said light chain and heavy chain above were ligated into the highly efficient Eukaryotic cell expression vector to obtain the light chain and heavy chain Eukaryotic expression vector.
Example 2: Selection and engineering of the host cell
In the biopharmaceutical field selection of host cells needs to focus on several important aspects: glycosylation and other post-translational modifications types to avoid causing immunogenicity； host cells suitable for large-scale cultivation in bioreactors, and can grow to high density in chemically defined and animal component free (ACDF) medium； virus safety； suitable for cloning and pressure screening in the ACDF.
CHO cell can grow at high density in bioreactors, is easy for genetic manipulation, has N-glycosylation similar to humans, lower the risk of virus transmission, and is widely used in the biopharmaceutical field. The most commonly used clone for industrial production is the CHO-K1, CHO-DXB11 and CHO-DG44. CHO-K1 is similar to the primary CHO cell, while DG44 and DXB11 were manipulated through random mutagenesis to remove DHFR gene, so they can be used for gene amplification via metabolic defects. CHO-K1 uses CS selection system, but has a lower screening efficiency because of the endogenous CS expression in CHO-K1.
The present invention chose the more widely used CHO cells as host cells which are more suitable for industrial production of therapeutic antibodies, and performed proper engineering of CHO-K1. We used CRTSPR/Cas techniques to knockout the CS gene of CHO-K1, and obtained cell line designated as CHO-CR-GS-/-, eliminating the expression of the endogenous CS, which is therefore more beneficial for screening of high expression cell clones.
Example 3: Transfecting host cells and screening high expression clones
Liposome based cotransfection of CHO-CR-GS-/-, screening under the pressure of CS selection system were performed to obtain stable cell clones with highly efficient expression
of anti-EGFR monoclonal antibody. After several rounds of transfection and screening, cell clones were obtained with expressing amount greater than 20pg/cell. day.
Example 4: Identification of culture conditions
We have developed universal basal medium for CHO-CR-G5-/-, which is chemically defined type of medium (Chemical Defined, CD) , i.e. the medium is made by combining amino acids, vitamins, inorganic salt, glucose and trace elements according to cell growth needs and certain percentages. This basal medium can meet the initial growth needs of the engineered cells obtained from screening. In order to further improve the desired antibody yield from the engineered cells, optimizations were performed for the basal medium, including adding hormones, genetically engineered recombinant growth factors, adjusting amino acids amounts.
The culture PH is: 6.5 ～ 6.9, preferably pH6.6； culture temperature is: 33 ℃ ～ 36 ℃, preferably 34 ℃； osmolality is: 290mOsm/kg ～ 350 mOsm/kg, preferably 340 mOsm/kg.
After multiple comparisons and optimization, the culture (CHOM-B09) and supplemented medium (CHOM-S09) were ultimately determined suitable for the large scale serum-free culture of the engineered cells expressing anti-EGFR monoclonal antibody, with culture conditions: pH6.6, temperature 34 ℃, and osmotic pressure of 340 mOsm/kg.
The expression yield of the engineered cells is greater than 30pg/cell. day in the optimized medium, using Fed-batch culture mode. The yield of the desired antibody may be greater than 3g/L in the culture supernatant harvested after 2 weeks of culture period.
Example 5: Purification and isolation of CMAB009 antibody
The high expression clone obtained from the screening was cultured in expanded scale with serum-free culture medium, supernatant was collected, centrifuged at 9000rpm *20min, 4 ℃, pellet and the cell debris was discarded. concentrated by ultrafiltration using ultrafiltration packets of 50KB membrane from Millipore Corporation, then centrifuged at 9000rpm *30min, 4 ℃ to remove cell debris, filtered with 0.45um membrane, used rProtein A (recombinant protein a) by affinity chromatography to do preliminary purification, in-situ
wash buffer is 6M GuCl, the binding buffer for the column is 20mM PB + 150mM NaC1 pH7.0, after balancing with three to five column volumes, using three to five column volumes of elution buffer 20mM Citric Acid (citrate buffer) pH3.0 to elute. Column is stored in 20 ％ EtOH after equilibration and washing. The eluted desired protein from rProteinA was desalted and buffer exchanged using Hitrap G25 (GE Healthcare) , the column elution buffer is PBS (20mM PB + 150mM NaC1 pH7.0) , in-situ washing solution is 0.5M NaOH. All of the above purification steps were performed on ice, the antibodies obtained from purification were concentrated with 50KD ultrafiltration centrifuge tubes (Merck Millipore) and to give CMAB009 monoclonal antibody.
Following purification, CMAB009 was characterized according to standard dynamic light scattering (DLS) analysis. It was determined that CMAB009 has a more homogenous size distribution in comparison to Erbitux. The z-average (z-avg) for Erbitux was determined to be 31.56 nm, while the z-avg. for CMAB009 was 16.79 nm. Furthermore, the polydispersity index (PDI) of Erbitux was determined to be 0.313, versus 0.128 for CMAB009. The characterization of CMAB009 versus Erbitux using DLS methods to determine size distribution was shown in Fig 7.
Example 6: Comparison of the glycosylation of the culture product
LC /MS, MS/MS techniques were used for the comparative analysis of the sugar chains of CMAB009 monoclonal antibody and Cetuximab (
C225 monoclonal antibody) .
Sample preparation: Fc fragment and oligosaccharide from Fab were prepared after glucosidase digestion； oligosaccharides exonuclease treatment of oligosaccharides on Fab； 2-AB fluorescence labeling of oligosaccharides； After HILIC solid phase extraction to remove excess 2-AB, oligosaccharides were obtained with fluorescence labeled sugar chains, then analyzed via LC/MS and MS/MS chromatography.
The free glycans from glycosidase treatment of MAb, after fluorescent labeling, will be analyzed respectively by LC/MS, MS/MS and oligosaccharide exonuclease treatment. The results show that, CMAB009 antibody and the original antibody Cetuximab
each have two glycosylation sites, with exactly the same glycan chain structure on their Fc segments, results in Figure 1. But Fab segments have different glycan chain structures, with
mostly the sialic acid NANA glycan chain structure on CMAB009 Fab fragment, and mostly the sialic acid NGNA glycan chain structure on original Cetuximab Fab fragment； The glycans of CMAB009 Fab do not contain α-galactose, while the glycans of original Cetuximab Fab contain a large amount of α-galactose. LC/MS analysis of the glycan structure of the heavy chain Fab fragment is shown in Figure 2.
Example 7: Clinical tolerance study
Initial evaluation of CMAB009 mAb clinical tolerance
An initial study enrolled a total of 18 subjects, with 3, 6, 6 subjects each assigned to dose groups of 100 mg/m2 dose, 250 mg/m2 dose and 400 mg/m2 dose, respectively, in the study of single intravenous administration. Among the subjects enrolled in single dose study, 3 subjects withdrew due to disease progression, according to the study design the remaining 15 subjects multiple administration inclusion criteria were enrolled in the multiple dose group meeting, with 3 extra subjects were enrolled to multiple dose (Table 1)
Table 1. Allocation of patients to the different dose groups
| Patient No. | Single-dose phase | Multiple-dose phase |
| #01 | 100mg/m2 | Group A |
| #02 | 100mg/m2 | Disease progression |
| #03 | 100mg/m2 | Group A |
| #04 | 250mg/m2 | Group A |
| #05 | 250mg/m2 | Group A |
| #06 | 250mg/m2 | Group A |
| #07 | 250mg/m2 | Group A |
| #08 | 250mg/m2 | |
| # | ||
| 09 | 250mg/m2 | Group B |
| #10 | 400mg/m2 | |
| # | ||
| 11 | 400mg/m2 | Disease progression |
| #12 | 400mg/m2 | Group B |
| #13 | 400mg/m2 | Group B |
| #14 | 400mg/m2 | Disease progression |
| #15 | 400mg/m2 | Group B |
| #16 | - | Group B |
| #17 | - | Group B |
| #18 | - | Group B |
Subjects enrolled in this study were refractory to effective conventional treatment methods, experienced failure from conventional treatment or patients with relapse of advanced cancers,
including 10 cases of colorectal cancer, 7 cases of lung cancer, 1 case of gastric cancer, the demographic statistical characteristics and prior treatment of the subjects are shown in Table 2.
Table 2. Patient characteristics
| No.patients | |
| Total | 18 |
| Treated on fixed does extension phase | 14 |
| Median age， y (range) | 52 (29-64) |
| Sex | |
| Male | 9 |
| Female | 9 |
| Tumor type | |
| Colorectal | 10 |
| NSCLC | 7 |
| Gastric | 1 |
| No. |
|
| 2 | 7 |
| 3 | 4 |
| ≥3 | 4 |
| Radiotherapy | 7 |
Comparison and analysis were performed on subjects’ baselines, and the age, height, weight, body surface, ECOG score of subjects from the three groups of single dose and the two groups of multiple doses. The results are shown in Table 3 with no statistically significant difference.
Table 3. Subject characterstics at baseline. Mean±SD
The results showed that the CMAB009 monoclonal antibody was well tolerated. Among the 18 subjects, there was no grade III-IV drug-related toxicity as showed in Table 4, with all occurring drug-related toxicity at grade I-II, and the incidence of toxicity was independent of the doses or the dosing frequency. No dose-limiting toxicity was observed, and no drug-related hypersensitivity was observed.
Table 4. CMAB009-related toxicities
There was no CMAB009 antibody related hypersensitivity observed in this study, while the findings by Paula M. Fracasso and others indicated that the incidence of hypersensitivity reactions associated with
reached 31％, of which class III-IV hypersensitivity
incidence is 13％. Christine H. Chung and others conducted research on the hypersensitivity occurring in administering of original
(Chung CH, Mirakhur B, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1, 3-galactose. N Engl J Med 2008； 358 (11) : 1109-17) . Among 76 subjects who received
treatment, 25 subjects had hypersensitivity, with hypersensitivity incidence reached 33％, which is consistent with the results by Paula M. Fracasso. Christine H. Chung’s study confirmed
related hypersensitivity is α-Gal-specific IgE-mediated.
Example 8: Clinical result safety, immunogenicity study
CMAB009 monoclonal antibody clinical safety: most adverse events were drug-related rash, there were no clinically significant new toxicity observed, and there no was severe hypersensitivity observed among the 73 subjects.
Immunogenicity is an important aspect in biopharmaceutical safety assessment. Traditional ELISA can be used for immunogenicity analysis, but the problem is, theoretically, the coated Fab segments for capturing antibody should be oriented to the optimal confirmation to facilitate the antigen-antibody interaction, the Fab fragments for capturing sometimes ae partially or entirely bound to microtiter plates, which results in the reduction of antibody capturing activity.
In this study, the biosensors made with biofilm interference technology and optical fibers were employed, in which the bottom was covered with SA ligands conjugated with biomolecule compatible layers. Once the captured biotinylated antibody is bound to the ligands, the biofilm thickness increases, reflected light interference spectral curve drift a measurable distance, thereby enabling real-time measurement of intermolecular interactions. This method is equivalent to the self-assembly process of the captured antibodies, which formed a range of optimal conformations at a certain density for capturing antibody on the surface of the biosensor, which not only improves the analytical sensitivity but also increases the linear range, which helps reduce the false-positive reactions from non-specific binding.
Fortebio Octet immunogenicity analysis: examination of ADA in clinical serum samples, the results shown in Figure 3, 4: cut point value analysis showed that there were 3 subjects of
potentially positive in 73 subjects (HPC highly positive, MIPC is positive, LPC is low positive, NC negative) .
As to the immunogenicity analysis of CMAB009 monoclonal antibody in this study, the results showed that there was ADA detected in 1.4％ (1/73) of the subjects, with IgG type confirmed by subtype analysis, which are not the IgE type ADA mediated by hypersensitivity. The results of this study is consistent with the results of clinical safety evaluation, since there was no severe hypersensitivity reactions observed among subjects in clinical studies.
Example 9: CMAB009 treatment results in improved efficacy for treating cancer and reduced immunogenicity
CMAB009 was administered to patients having metastatic colorectal cancer in a Phase 2/3 study to determine the efficacy and immunogenicity of CMAB009. As described below, the results from the study were then compared to similar studies performed using
(cetuximab) . Surprisingly, it was determined that CMAB009 has additional efficacy beyond that known for
For example, CMAB009 was able to increase the overall survival and length of time to disease progression in patients. The below study is comparable to the 
(cetuximab) study described in Alberto F. Sobrero, et al. Clin Oncol, 2008, 26: 2311-2319.
The CMAB009 study was initiated by screening patients to identify those with 1) histological confirmed metastatic colorectal adenocarcinoma, 2) KRAS wild-type tumors, EGFR-expressing or EGFR-noexpressiong by immunohistochemistry, 3) has measurable lesion, at least 1cm in diametre by CT or MRI, at least 2cm diameter by physical examination or other iconography, 4) ECOG performance status 0 to 1, 5) failure (disease progression/discontinuation due to toxicity ) of fluoropyrimidine and oxaliplatin treatment, stop at least one month thereafter, 
. 501 patients were identified and randomized in a 2: 1 manner to group 1 or group 2. Group 1 included 337 patients who were administered a combination of CMAB009 and irinotecan. Specifically, the patients in group 1 were administered an initial dose of 400 mg/m2 of CMAB009 followed by weekly infusions of 250 mg/m2 thereafter. Irinotecan doses were maintained 180mg/m2 every 2 weeks. Group 2 included 164 patients who were administered irinotecan monotherapy at a dose consistent with the patient’s therapy prior to the study. Patients in both groups were treated
until the disease progressed or the patient reached an unacceptable level of toxicity. Patient baseline characteristics are provided in Table 5.
Table 5. Baseline characteristics
Patients were evaluated for radiologic response in both group 1 and group 2. The results are described in Table 6. Note the overall response rate (ORR) in Table 6 was determined according to the sum of the rate of CR and PR, and the disease control rate (DCR) was determined according to the sum of the rates of CR, PR, and SD.
When compared to data reported for
(cetuximab) from a similar study (see Alberto F. Sobrero, et al. Clin Oncol, 2008, 26: 2311-2319) , patients receiving CMAB009 showed better overall survival (10.7 months for patients receiving
(cetuximab) + irinotecan vs. 17.6 months for patients receiving CMAB009 + irinotecan) and an incrased time to disease progression (4.0 months for patients receiving
(cetuximab) + irinotecan vs, 5.6 months for patients receiving CMAB009 + irinotecan) .
Table 6. Radiologic response of CMAB009 compared with Erbitux
When compared to reported data for
surprisingly the overall survival of the patients was greater in the patients receiving CMAB009, i.e., 10.7 months for Erbitux (cetuximab) + irinotecan vs. 17.5 months for CMAB009 + irinotecan. Data showing an increase in disease progression from this CMAB009 study is also provided in Figure 5 (compare to published Erbitux (cetuximab) data； see Figure 3 of Alberto F. Sobrero, et al. Clin Oncol, 2008, 26: 2311-2319. Data showing an increase in overall survival from this CMAB009 study is also provided in Figure 6 (compare to published Erbitux (cetuximab) data； see Figure 2 of Alberto F. Sobrero, et al. Clin Oncol, 2008, 26: 2311-2319) .
A safety evaluation of the study is provided below in Table 7.
Table 7. Safety evaluation
Notably, adverse events from the CMAB009 study were lower than those reported for 
(cetuximab) . The grade 3-4 adverse events are described below in Table 8 (compare to Table 3 of Alberto F. Sobrero, et al. Clin Oncol, 2008, 26: 2311-2319) .
Table 8. Grade 3-4 adverse events for CMAB009 study
In sum, despite having the same primary structure, CMAB009 surprisingly was not only more effective than Erbitux (cetuximab) , providing, for example, a longer time to disease progression, but had a reduced rate of adverse events associated with hypersensitivity reactions, e.g., acne-like rash or diarrhea.
Claims (36)
- A novel method of producing an anti-EGFR monoclonal antibody, said method comprising:a) a novel anti-EGFR monoclonal antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO: 2 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 4；b) constructing recombinant plasmid using nucleic acid fragment of a) , transfecting host cell, screening high-expressing clone；c) optimizing cell culture conditions, culturing in large scale to produce novel anti-EGFR monoclonal antibody, isolating and purifying.
- The method of claim 1, wherein the coding sequences for the light chain and heavy chain of the novel anti-EGFR monoclonal antibody are designed and synthesized according to the codons mostly preferred by Chinese hamster.
- The method of claim 1, wherein said host cell is Eukaryotic mammalian CHO cell.
- The method of claim 1, wherein said cell culture temperature is 33 ℃ ～ 36 ℃, preferably 34℃.
- The method of claim 1, wherein said pH of the cell culture growth media is 6.5～6.9, preferably pH6.6.
- The method of claim 1, wherein said osmotic pressure of the cell culture growth media is 290 mOsm/kg～ 350mOsm/kg, preferably 340mOsm/kg.
- The method according to any one of claims 4, 5, 6, wherein the cell culture growth media is serum-free cell culture growth media, and the host cell is cultured in serum-free condition.
- The novel antibody of claim 1 has lower immunogenicity than the antibodies produced with conventional methods.
- A composition comprising the antibody of claim 1, and a pharmaceutically acceptable carrier.
- A method of producing drug comprising the novel anti-EGFR monoclonal antibody of claim 1 to treat tumors expressing epidermal growth factor receptor (EGFR) .
- A method of treating tumors expressing epidermal growth factor receptor (EGFR) with drug comprising the composition of claim 9.
- A method according to any one of claims 10, 11, further comprising administering in combination with other drugs treating tumors expressing epidermal growth factor receptor (EGFR) .
- A liquid pharmaceutical composition comprising water and an anti-EGFR antibody,wherein the anti-EGFR antibody comprises a light chain comprising the amino acid sequence set forth in SEQ ID NO: 2 and a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 4,wherein the antibody has a z-average (z-avg) of about 10-25 nm as determined by dynamic light scattering (DLS) analysis, andwherein the anti-EGFR antibody does not comprise an N-glycolylneuraminic acid (NGNA) , does not comprise a Gal-α (1, 3) -Gal glycan, and/or does comprise a Gal-α (2, 3/6) -Gal glycan.
- The composition of claim 13, wherein the z-avg of the antibody is 15-20 nm.
- A method of treating a human subject having cancer, said method comprising administering the composition of claim 13 or 14 to the subject, such the cancer is treated.
- A method of inhibiting progression of cancer in a human subject, said method comprising administering the composition of claim 13 or 14 to the subject, such progression is inhibited.
- The method of claim 15 or 16, wherein the cancer is squamous cell carcinoma of the head and neck (SCCHN) or colorectal cancer.
- The method of claim 17, wherein the colorectal cancer is K-Ras Wild-type, EGFR-expressing colorectal cancer.
- The method of claim 18, wherein the antibody is administered in combination with FOLFIRI (irinotecan, 5-fluorouracil, leucovorin) .
- The method of claim 18, wherein the antibody is administered in combination with irinotecan.
- The method of claim 15 or 16, wherein the subject has recurrent or metastatic squamous cell carcinoma of the head and neck and has failed prior platinum-based therapy.
- The method of claim 15 or 16, wherein the subject has locally or regionally advanced squamous cell carcinoma of the head and neck.
- The method of claim 22, wherein the antibody is administered in combination with radiation therapy for the initial treatment of the cancer.
- The method of claim 15 or 16, wherein the subject has recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck.
- The method of claim 21, wherein the antibody is administered in combination with platinum-based therapy with 5-FU.
- The method of claim 15 or 16, wherein the antibody is administered in combination with an additional therapeutic agent.
- The method of claim 26, wherein the additional therapeutic agent is a chemotherapeutic agent.
- The method of claim 15 or 16, wherein the subject has failed oxaliplatin and irinotecan-based chemotherapy.
- The method of claim 15 or 16, wherein the subject is intolerant to irinotecan.
- A method of treating or inhibiting progression of colorectal cancer in a subject having colorectal cancer, said method comprising administering an anti-EGFR antibody and irinotecan, such that colorectal cancer is treated, wherein the antibody comprises a light chain comprising the amino acid sequence set forth in SEQ ID NO: 2, comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 4, and contains a Gal-α (2, 3/6) -Gal glycan.
- A method of treating or inhibiting progression of colorectal cancer in a subject having colorectal cancer, said method comprising administering an anti-EGFR antibody and irinotecan, such that colorectal cancer is treated, wherein the antibody comprises a light chain comprising the amino acid sequence set forth in SEQ ID NO: 2, comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 4, and does not contain either an N-glycolylneuraminic acid (NGNA) glycan or a Gal-α (1, 3) -Gal glycan.
- The method of claim 31 or 32, wherein the colorectal cancer is advanced colorectal cancer.
- The method of any one of claims 31-33, wherein the antibody is administered via infusion to the subject at an initial dose of 400 mg/m2 followed by a weekly dose of 250 mg/m2.
- The method of any one of claims 31-34, wherein the antibody is produced in a Chinese Hamster Ovary (CHO) cell.
- A liquid pharmaceutical composition comprising water and an anti-EGFR antibody,wherein the anti-EGFR antibody comprises a light chain comprising the amino acid sequence set forth in SEQ ID NO: 2 and a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 4,wherein the anti-EGFR antibody is produced in a Chinese Hamster Ovary (CHO) cell,and wherein the composition does not comprise a polysorbate and/or a saccharobiose.
- A liquid pharmaceutical composition consisting essentially of water, an anti-EGFR antibody, sodium chloride, sodium dihydrogen phosphate dihydrate, and disodium phosphate dihydrate,wherein the anti-EGFR antibody comprises a light chain comprising the amino acid sequence set forth in SEQ ID NO: 2 and a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 4, andwherein the anti-EGFR antibody does not comprise an N-glycolylneuraminic acid (NGNA) glycan, does not comprise a Gal-α (1, 3) -Gal glycan, and/or does comprise a Gal-α (2, 3/6) -Gal glycan.
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16734886.1A EP3242895A4 (en) | 2015-01-07 | 2016-01-04 | A novel anti-egfr monoclonal antibody, method of making, and use thereof |
| JP2017554631A JP6643356B2 (en) | 2015-01-07 | 2016-01-04 | Novel anti-EGFR monoclonal antibody, its production method and its application |
| CA2973163A CA2973163C (en) | 2015-01-07 | 2016-01-04 | A novel anti-egfr monoclonal antibody, method of making, and use thereof |
| US15/541,291 US10118966B2 (en) | 2015-01-07 | 2016-01-04 | Anti-EGFR monoclonal antibody, methods of making, and uses thereof in the treatment of cancer |
| AU2016206155A AU2016206155B2 (en) | 2015-01-07 | 2016-01-04 | A novel anti-EGFR monoclonal antibody, method of making, and use thereof |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510006233.7 | 2015-01-07 | ||
| CN201510006233.7A CN105820248A (en) | 2015-01-07 | 2015-01-07 | Method for preparing novel anti-EGFR monoclonal antibody and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2016110226A1 true WO2016110226A1 (en) | 2016-07-14 |
Family
ID=56355522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2016/070024 WO2016110226A1 (en) | 2015-01-07 | 2016-01-04 | A novel anti-egfr monoclonal antibody, method of making, and use thereof |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10118966B2 (en) |
| EP (1) | EP3242895A4 (en) |
| JP (1) | JP6643356B2 (en) |
| CN (1) | CN105820248A (en) |
| AU (1) | AU2016206155B2 (en) |
| CA (1) | CA2973163C (en) |
| WO (1) | WO2016110226A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106497881A (en) * | 2016-09-13 | 2017-03-15 | 广州白云山拜迪生物医药有限公司 | Stability and high efficiency expression recombined human hyaluronidase CHO K1SP cell lines and its construction method |
| CN110835375B (en) * | 2018-08-16 | 2021-04-06 | 上海洛启生物医药技术有限公司 | anti-PD-1/EGFR bispecific antibody and application thereof |
| CN114832102B (en) * | 2021-02-02 | 2024-10-22 | 盛禾(中国)生物制药有限公司 | Stable anti-EGFR antibody composition |
| CN115300623B (en) * | 2021-05-08 | 2024-06-21 | 盛禾(中国)生物制药有限公司 | Compositions of anti-EGFR fusion proteins or antigen binding fragments thereof and uses thereof |
| WO2023015234A1 (en) * | 2021-08-05 | 2023-02-09 | Bristol-Myers Squibb Company | Cell culture methods for producing therapeutic proteins |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004085474A2 (en) * | 2003-03-20 | 2004-10-07 | Imclone Systems Incorporated | Method of producing an antibody to epidermal growth factor receptor |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100494370C (en) * | 2006-05-26 | 2009-06-03 | 神州细胞工程有限公司 | Optimized monoclonal antibody |
| KR20170021375A (en) * | 2006-09-10 | 2017-02-27 | 글리코토페 게엠베하 | Use of human cells of myeloid leukaemia origin for expression of antibodies |
| US8586356B2 (en) * | 2009-01-22 | 2013-11-19 | Momenta Pharmaceuticals, Inc. | Gal α1-3gal-containing N-glycans in glycoprotein products derived from CHO cells |
| CN102219855B (en) * | 2010-04-15 | 2016-04-06 | 上海抗体药物国家工程研究中心有限公司 | A kind of monoclonal antibody against EGFR of high-affinity |
| CA2833477A1 (en) * | 2011-04-21 | 2012-10-26 | Seattle Genetics, Inc. | Novel binder-drug conjugates (adcs) and their use |
| DK2991683T3 (en) * | 2013-05-02 | 2019-11-04 | Glykos Finland Oy | CONJUGATES OF A GLYCOPROTEIN OR A GLYCAN WITH A TOXIC CHARGE |
| WO2017120613A1 (en) * | 2016-01-10 | 2017-07-13 | Sorrento Therapeutics, Inc. | Improved safety for treating cancers with a glycosylated chimeric antibody to egfr |
-
2015
- 2015-01-07 CN CN201510006233.7A patent/CN105820248A/en active Pending
-
2016
- 2016-01-04 AU AU2016206155A patent/AU2016206155B2/en active Active
- 2016-01-04 WO PCT/CN2016/070024 patent/WO2016110226A1/en active Application Filing
- 2016-01-04 JP JP2017554631A patent/JP6643356B2/en active Active
- 2016-01-04 US US15/541,291 patent/US10118966B2/en active Active - Reinstated
- 2016-01-04 CA CA2973163A patent/CA2973163C/en active Active
- 2016-01-04 EP EP16734886.1A patent/EP3242895A4/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004085474A2 (en) * | 2003-03-20 | 2004-10-07 | Imclone Systems Incorporated | Method of producing an antibody to epidermal growth factor receptor |
Non-Patent Citations (5)
| Title |
|---|
| ALBERTO F. SOBRERO ET AL., CLIN ONCOL, vol. 26, 2008, pages 2311 - 2319 |
| CHUNG CHMIRAKHUR B ET AL.: "Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3- galactose", N ENGL J MED, vol. 358, no. 11, 2008, pages 1109 - 17 |
| DUANG, X. ET AL.: "Research advances of animal cell culture medium for producing antibody drugs", CHINESE MEDICINAL BIOTECHNOLOGY, vol. 9, no. 1, 28 February 2014 (2014-02-28), pages 53, XP009504526 * |
| See also references of EP3242895A4 |
| SONG, S. ET AL.: "Advances in medical treatment of metastatic colorectal cancer", CHINA ONCOLOGY, vol. 16, no. 10, 28 October 2006 (2006-10-28), pages 777, XP009504540 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20180030139A1 (en) | 2018-02-01 |
| AU2016206155B2 (en) | 2018-05-24 |
| JP2018508227A (en) | 2018-03-29 |
| US10118966B2 (en) | 2018-11-06 |
| CA2973163C (en) | 2020-04-07 |
| EP3242895A1 (en) | 2017-11-15 |
| AU2016206155A1 (en) | 2017-07-27 |
| CN105820248A (en) | 2016-08-03 |
| EP3242895A4 (en) | 2018-07-18 |
| JP6643356B2 (en) | 2020-02-12 |
| CA2973163A1 (en) | 2016-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2973163C (en) | A novel anti-egfr monoclonal antibody, method of making, and use thereof | |
| CN110621336B (en) | Combination of anti-FGFR 2 antibodies and chemotherapeutic agents in cancer treatment | |
| US20160068609A1 (en) | Anti-cancer treatments with anti-egfr antibodies having a low fucosylation | |
| US11820824B2 (en) | Antibodies to TIGIT | |
| JP2022518399A (en) | How to Treat Cancer with PD-1 Axial Binding Antagonists and RNA Vaccines | |
| Fiedler et al. | Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas | |
| US9963506B2 (en) | Human-mouse chimeric anti-CD147 antibody with non-fucosylated glycosylation | |
| TW202321309A (en) | Treatment of immune checkpoint inhibitor-treated cancers with high egfr expression using an antibody that binds at least egfr | |
| EP4403188A1 (en) | Antibody drug conjugate formulation and use thereof | |
| JP7536085B2 (en) | Treatment of cancer using a combination of antibodies that bind to LGR5 and EGFR and a topoisomerase I inhibitor - Patent Application 20070123333 | |
| CN114793422A (en) | anti-CTLA-4 monoclonal antibody and preparation method and application thereof | |
| CN107987161B (en) | anti-EGFR monoclonal antibody preparation | |
| EP4223777A1 (en) | Anti-cd3 antibody and uses thereof | |
| CN111032081A (en) | ErbB-2 and ErbB-3 targeting agents and bispecific antibodies | |
| EP4190818A1 (en) | Anti-her2 antibody and use thereof | |
| EP4026560A1 (en) | Therapeutic agent for polycythemia | |
| TW201642904A (en) | Composition comprising anti-FGFR2 antibody and other agent | |
| JP2023523006A (en) | Cancer treatment with antibodies that bind to LGR5 and EGFR | |
| WO2024002074A1 (en) | Pharmaceutical composition comprising mixed antibody of anti-ctla4 and anti-pd1 and therapeutic use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16734886 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 15541291 Country of ref document: US |
|
| ENP | Entry into the national phase |
Ref document number: 2973163 Country of ref document: CA |
|
| ENP | Entry into the national phase |
Ref document number: 2017554631 Country of ref document: JP Kind code of ref document: A |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 2016206155 Country of ref document: AU Date of ref document: 20160104 Kind code of ref document: A |
|
| REEP | Request for entry into the european phase |
Ref document number: 2016734886 Country of ref document: EP |